Prakash Prabhakar

Prakash Prabhakar, PhD has extensive experience in various roles within the pharmaceutical and biotech industry. Prakash currently holds the position of Vice President, Clinical Operations & Translational Early Clinical Development at Obsidian Therapeutics. Prior to that, they served as the Sr. Director Clinical Development Operations at Ultragenyx Pharmaceutical Inc., where they were responsible for clinical development of a gene therapy for the treatment of Glycogen Storage Disease Ia (GSDIa). Prakash also worked as the Sr. Director, Program Management & Clinical Operations at TCR2 Therapeutics Inc., overseeing activities ranging from preclinical development to regulatory submissions for cell and gene therapy products. Prakash has held positions at Intarcia Therapeutics, Inc., PerkinElmer, Interleukin Genetics, Surface Logix, Vertex Pharmaceuticals, Inc., Harvard Medical School, and Brigham and Women's Hospital, contributing to various aspects of clinical operations, program management, and research. Prakash has successfully led the approval of several INDs and orphan drug designations, and has provided strategic leadership and operational expertise throughout their career. Prakash's expertise spans a wide range of therapeutic areas, including gene therapy, cell therapy, obesity, inflammatory diseases, and prenatal screening.

Prakash Prabhakar holds a PhD in Biotechnology-Biochemistry from Banaras Hindu University. Additionally, they are a Certified Clinical Research Professional (CCRP) from the Society of Clinical Research Associates (SoCRA).